# Johnathan Matlock

> Johnathan Matlock is a seed investor at Science Angel Syndicate backing Medical and Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Science Angel Syndicate](https://shizune.co/investors/profile/science-angel-syndicate)
- Location: Bedford, United Kingdom
- Total investments: 9
- Last investment: May 2023
- Lead investor: 56%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/johnathanmatlock/

Johnathan Matlock is a seed investor at Science Angel Syndicate in Bedford focused on Medical and Biotechnology. Johnathan Matlock is Co-Founder Science Angel Syndicate.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.3M–$6.1M |
| Pre-Seed | $1.1M–$1.1M |
| Venture - Series Unknown | $2.3M–$6M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 44% |
| Biotechnology | 3 | 33% |
| Health Care | 2 | 22% |
| Life Science | 2 | 22% |
| Robotics | 1 | 11% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 56% |
| Pre-Seed | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Halo Therapeutics | Halo Therapeutics develops antivirals to prevent users from sickness. It researches on virus shapes and creates fatty acids into medicine to lock them. Halo Therapeutics was founded in 2020 and is based in Bristol, England. | $1.9M | Seed | May 17, 2023 |  |
| OSSTEC | OSSTEC is bringing advanced technology to the operating room with metal 3D printed bone healing implants. The orthopaedic implants emulate natural bone structure and address high failure rates of existing implants, keeping patients who suffer with osteoarthritis healthy, active and enjoying life. | $1.5M | Seed | Mar 30, 2023 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M | Pre-Seed | Jan 17, 2023 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $1.1M | Pre-Seed | Jan 17, 2023 |  |
| QV Bioelectronics | Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M | Seed | Jan 10, 2023 |  |
| QV Bioelectronics | Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $2.4M | Seed | Jan 10, 2023 |  |
| cheMastery | CheMastery is a company that creates laboratory automation technology. They provide automation solutions for chemical laboratories in order to facilitate the manufacturing and R&D processes in the chemical sector. It makes science more effective and reliable for scientists in the chemical sector. |  | Seed | Nov 13, 2022 |  |
| Zentraxa | Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existingbio-design limits imposed by conventional peptide synthesis, with one universal process. |  | Seed | May 27, 2022 |  |
| Zentraxa | Zentraxa’s proprietary technological platform, Zentide, combined with our extensive technical know-how allows us to push the boundaries of what can be achieved with synthetic biopolymers. We specialise in the design, production and testing of complex novel peptides and, as a result of our Zentide platform, can circumvent previously existingbio-design limits imposed by conventional peptide synthesis, with one universal process. |  | Seed | May 27, 2022 |  |

9 of 9 investments shown.

## Co-investors
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 8 deals together
- [Elbow Beach Capital](https://shizune.co/investors/profile/elbow-beach-capital) — VC Fund, 5 deals together
- [The Fink Family Office](https://shizune.co/investors/profile/the-fink-family-office) — VC Fund, 5 deals together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 4 deals together
- [Science Angel Syndicate](https://shizune.co/investors/profile/science-angel-syndicate) — VC Fund, 4 deals together
- [Bristol Private Equity Club](https://shizune.co/investors/profile/bristol-private-equity-club) — VC Fund, 2 deals together

## About Science Angel Syndicate

VC Fund · Bristol, United Kingdom

Science Angel Syndicate is a entrepreneurs and investors source world class scientific discoveries that impact society on a global scale.

1 contacts available at Science Angel Syndicate.

| Name | Title | Profile |
| --- | --- | --- |
| Johnathan Matlock | Co-Founder | https://shizune.co/investors/profile/johnathan-matlock |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Life Science Angel Investors in Europe](https://shizune.co/investors/life-science-angel-investors-europe)
- [Life Science Angel Investors in United Kingdom](https://shizune.co/investors/life-science-angel-investors-united-kingdom)
- [Medical Angel Investors in United Kingdom](https://shizune.co/investors/medical-angel-investors-united-kingdom)
- [Biotechnology Angel Investors in United Kingdom](https://shizune.co/investors/biotechnology-angel-investors-united-kingdom)
- [Biotech Angel Investors in United Kingdom](https://shizune.co/investors/biotech-angel-investors-united-kingdom)

## FAQ

### What does Johnathan Matlock invest in?

Johnathan Matlock invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Johnathan Matlock's check size?

Johnathan Matlock typically joins rounds of $1.3M–$6.1M at Seed, $1.1M–$1.1M at Pre-Seed and $2.3M–$6M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Johnathan Matlock participates in.

### When did Johnathan Matlock last invest?

The most recent investment recorded for Johnathan Matlock closed in May 2023. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co